US 12,168,015 B2
Aryl-or heteroaryl-substituted benzene compounds
Kevin W. Kuntz, Woburn, MA (US); Richard Chesworth, Concord, MA (US); Kenneth W. Duncan, Westwood, MA (US); Heike Keilhack, Belmont, MA (US); Natalie Warholic, Cambridge, MA (US); Christine Klaus, Waban, MA (US); Sarah K. Knutson, Lincoln, MA (US); Timothy J. N. Wigle, Waltham, MA (US); Masashi Seki, Tsukuba (JP); Syuji Shirotori, Tsukuba (JP); and Satoshi Kawano, Tsukuba (JP)
Assigned to Epizyme, Inc., Cambridge, MA (US)
Filed by Epizyme, Inc., Cambridge, MA (US)
Filed on Mar. 15, 2024, as Appl. No. 18/606,925.
Application 18/606,925 is a continuation of application No. 17/308,610, filed on May 5, 2021, abandoned.
Application 17/308,610 is a continuation of application No. 16/660,339, filed on Oct. 22, 2019, granted, now 11,052,093, issued on Jul. 6, 2021.
Application 16/660,339 is a continuation of application No. 16/291,800, filed on Mar. 4, 2019, abandoned.
Application 16/291,800 is a continuation of application No. 15/816,907, filed on Nov. 17, 2017, granted, now 10,420,775, issued on Sep. 24, 2019.
Application 15/816,907 is a continuation of application No. 15/598,078, filed on May 17, 2017, granted, now 9,855,275, issued on Jan. 2, 2018.
Application 15/598,078 is a continuation of application No. 15/346,677, filed on Nov. 8, 2016, granted, now 10,155,002, issued on Dec. 18, 2018.
Application 15/346,677 is a continuation of application No. 14/876,658, filed on Oct. 6, 2015, granted, now 9,522,152, issued on Dec. 20, 2016.
Application 14/876,658 is a continuation of application No. 14/742,481, filed on Jun. 17, 2015, granted, now 9,549,931, issued on Jan. 24, 2017.
Application 14/742,481 is a continuation of application No. 14/275,667, filed on May 12, 2014, granted, now 9,090,562, issued on Jul. 28, 2015.
Application 14/275,667 is a continuation of application No. 13/722,807, filed on Dec. 20, 2012, granted, now 8,765,732, issued on Jul. 1, 2014.
Application 13/722,807 is a continuation of application No. 13/447,007, filed on Apr. 13, 2012, granted, now 8,410,088, issued on Apr. 2, 2013.
Claims priority of provisional application 61/499,595, filed on Jun. 21, 2011.
Claims priority of provisional application 61/474,821, filed on Apr. 13, 2011.
Prior Publication US 2024/0245697 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/5377 (2006.01); A61K 31/4412 (2006.01); A61K 31/443 (2006.01); A61K 31/4433 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01); A61K 31/551 (2006.01); A61K 31/553 (2006.01); C07D 213/64 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 491/08 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01)
CPC A61K 31/5377 (2013.01) [A61K 31/4412 (2013.01); A61K 31/443 (2013.01); A61K 31/4433 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); C07D 213/64 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 491/08 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01)] 2 Claims
 
1. A pharmaceutically acceptable salt of the following compound:

OG Complex Work Unit Chemistry
wherein the pharmaceutically acceptable salt is a hydrobromic acid salt.